BioCentury
ARTICLE | Clinical News

AKB-9778: Additional Phase IIa data

February 15, 2016 8:00 AM UTC

Additional data from the double-blind, U.S. Phase IIa TIME-2 trial in 144 patients with DME showed that twice-daily 15 mg subcutaneous AKB-9778 with and without once-monthly Lucentis ranibizumab led ...